Tyler’s Law
Summary
HR2004 'Tyler’s Law' is a procedural early-stage bill directing HHS to study fentanyl testing in emergency departments. It authorizes zero funding, imposes no mandates, and has languished in committee for over a year with no further action, producing no near-term market impact for any public company.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR2004 is a study-only bill with zero funding and no mandates—no market impact for any company.
- 2.Bill introduced 13+ months ago, referred to committee with zero subsequent actions; negligible passage probability.
- 3.No tickers meet causal chain threshold; diagnostic companies' revenues unaffected by this procedural bill.
Market Implications
$DGX at $194.67 on April 30 shows no price movement attributable to HR2004. The bill's existence has not altered the competitive landscape for diagnostic testing companies. Any future fentanyl testing mandate would require new legislation with funding authority, which is years away and currently nonexistent. No actionable market signal from this bill.
Full Analysis
HR2004 was introduced on March 10, 2025, and referred to the House Committee on Energy and Commerce, where it has remained for over 13 months with zero subsequent actions. The bill directs the Secretary of HHS to conduct a study on fentanyl testing frequency, costs, benefits, and patient impacts in emergency departments, and then issue guidance. Critically, the bill authorizes no funding for the study or any testing programs, and imposes no mandates on hospitals or testing companies. There is no mandatory timeline enforcement mechanism.
Because the bill is purely a study-and-guidance directive with zero authorized appropriations and no regulatory force, there is no direct revenue mechanism for any publicly traded company. Diagnostic testing companies like Quest Diagnostics ($DGX) and Laboratory Corporation of America ($LH) would only be affected if this study led to future mandated testing with reimbursement—a multi-year, multi-step legislative path that has not begun. Current legislation does not change their addressable market.
Looking at $DGX real market data, the stock closed at $194.67 on April 30, 2026, down 0.82% over 7 days and 0.67% over 30 days. Recent trading shows volatility from a high of $205.04 on April 21 to a low of $189.32 on April 29. These moves are driven by broader market factors and company fundamentals, not by HR2004, which has had no price-impacting events since its introduction.
Legislative path forward: the bill requires committee markup, House floor passage, Senate introduction and passage, and presidential action. With 54 cosponsors but no Senate companion bill and no committee activity in over a year, the probability of enactment during the 119th Congress is extremely low.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Some confirming evidence found across public data sources
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
SUPPORT for Patients and Communities Reauthorization Act of 2025
CHOICE for Veterans Act of 2025
ASAP Act
Supporting Healthy Moms and Babies Act
Reducing Hereditary Cancer Act
Thyroid Disease CARE Act of 2025
Increasing Access to Lung Cancer Screening Act
Access to Breast Cancer Diagnosis Act of 2025
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Ending Birth Tourism
This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →